Alder Biopharmaceuticals Inc (ALDR.OQ)
22 Sep 2017
* Alder Biopharmaceuticals announces second quarter 2017 financial and operating results
* Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock
Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectations, sending its shares plunging as much as 26 percent to a more than two-and-half year low.
* Shares fall as much as 26 pct to 2 1/2 yr-low (Adds analyst comment, updates shares)
* Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine
June 27 Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.
BRIEF-Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine
* Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24-48 hours after single infusion
* Alder Biopharmaceuticals announces first quarter 2017 financial and operating results
* Alder Biopharmaceuticals Inc - top-line results from promise 1 expected later this quarter Source text for Eikon: Further company coverage: